Improvement in Serum Magnesium Levels With Sodium-Glucose Cotransporter 2 Inhibitors

Abstract

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are associated with a modest but significant increase in serum magnesium levels. This report describes improvement in serum magnesium and associated symptoms after initiating SGLT2i therapy in a patient with refractory hypomagnesemia. A 58-year-old woman presented with persistent hypomagnesemia refractory to oral magnesium supplements. She had history of type 2 diabetes mellitus, hypothyroidism, fibromyalgia, and degenerative disk disease. The cause of hypomagnesemia was attributed to excessive renal losses. Laboratory investigations revealed serum magnesium of 1.2 mg/dL with fractional excretion of magnesium (FEMg) of 8.9%. She was started on Empagliflozin 10 mg daily. Within 4 weeks of therapy, her serum magnesium level corrected with symptomatic improvement, which was sustained a few weeks later. Subsequently, her oral magnesium supplements dose was reduced. SGLT2i has been shown to improve magnesium levels in patients with urinary magnesium wasting. Several mechanisms have been postulated but the exact physiology remains unknown. SGLT2i have been efficacious for glycemic control, renal protection, decreasing the risk of ASCVD events, and cardiac mortality in patients with diabetes. In addition, renal and cardiac benefits are also demonstrated in patients without diabetes. This observation demonstrates that SGLT2i can improve the management of patients with otherwise intractable hypomagnesemia.

Risk Factors for Acute Kidney Injury in Surgical Patients - A Review

“…SGLT2 inhibitors, by causing renal glycosuria, promote the growth and colonization of organisms in the genital tract. This phenomenon is intensified in patients with obstructive uropathy due to benign prostatic hypertrophy or neurogenic bladder and can result in infections [31]. Healthcare professionals should exercise prudence when prescribing medications to individuals at high risk, particularly those that have the potential to worsen renal vasoconstriction.…”

The Role of Sodium-Glucose Co-transporter 2 Inhibitors in Patients With Hypomagnesemia: A Systematic Review

“…reported a case where SGLT2 inhibitor therapy led to a rapid improvement in serum magnesium levels, reaching 2.2 mg/dL within four weeks. The sustained improvement on subsequent evaluations, coupled with reduced symptoms and a decreased oral magnesium supplement dose, suggested a positive therapeutic impact [ 12 ].…”